v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ (DEFICIT) EQUITY (unaudited) - USD ($)
$ in Thousands
Total
Common Shares
Additional Paid-in Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Balance at beginning of period (in shares) at Dec. 31, 2024   80,020,131      
Balance at beginning of period at Dec. 31, 2024 $ 3,298   $ 397,673 $ 6,361 $ (400,736)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss and other comprehensive loss (4,601)     110 (4,711)
Issued pursuant to restricted share unit awards (in shares)   1,098,511      
Issued pursuant to at-the-market offering agreements, net of issuance cost (in shares)   5,302,950      
Issued pursuant to at-the-market offering agreements, net of issuance cost 4,183   4,183    
Stock-based compensation expense 845   845    
Balance at end of period (in shares) at Mar. 31, 2025   86,421,592      
Balance at end of period at Mar. 31, 2025 $ 3,725   402,701 6,471 (405,447)
Balance at beginning of period (in shares) at Dec. 31, 2025 108,021,271 108,021,271      
Balance at beginning of period at Dec. 31, 2025 $ (3,799)   419,471 6,225 (429,495)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss and other comprehensive loss (9,243)       (9,243)
Issued pursuant to restricted share unit awards (in shares)   10,317      
Issued pursuant to at-the-market offering agreements, net of issuance cost (in shares)   7,446,574      
Issued pursuant to at-the-market offering agreements, net of issuance cost $ 7,614   7,614    
Issued pursuant to consulting services agreements (in shares) 650,000 650,000      
Issued pursuant to consulting service agreements $ 539   539    
Reclassification of warrants 77   77    
Stock option liability reclassification (1,189)   (1,189)    
Stock-based compensation expense $ 871   871    
Balance at end of period (in shares) at Mar. 31, 2026 116,128,162 116,128,162      
Balance at end of period at Mar. 31, 2026 $ (5,130)   $ 427,383 $ 6,225 $ (438,738)